Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:34:00.278Z.
Calculation as of: 2026-10-06T15:34:00.278Z.
Quote observation: 2026-10-06T15:29:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$147.54M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.97M
EV/EBIT Ratio
N/A
TTM Avg
1490.94x
3Y Avg
1490.94x
5Y Avg
1490.94x
Market Cap
$150.96M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$141.83M
EV/EBIT Ratio
N/A
TTM Avg
60.31x
3Y Avg
490.71x
5Y Avg
419.04x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $147.54M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | N/A | 1490.94x | 1490.94x | 1490.94x |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $146.12M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.96M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.60M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.63M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $151.93M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $141.83M | N/A | 60.31x | 490.71x | 419.04x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
